Article Sidebar
Published:
Apr 4, 2017DOI:
10.4314/tjpr.v16i3.5Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Elucidation of mechanism of Si-jun-zi decoction-induced reversal of spleen deficiency syndrome in rats by LC-QTOF/ MS metabolomics
Abstract
Purpose: To explore the therapeutic effect and mechanism of action of Si–jun–zi decoction (SJZD) in rat spleen deficiency syndrome.
Methods: Spleen deficiency syndrome was induced in a rat model with reserpine. Liquid chromatography quadrupole time-of-flight mass spectrometry (LC-Q-TOF/MS) and partial least squaresdiscriminate models (PLS-DA) were used to analyze the difference in global metabolite profile within all groups. Variable importance projection (VIP > 1) and Student’s t–test (p < 0.05) were used for biomarker selection.
Results: Enzymatic results showed that the level of amylase (AMY), pepsin (LPS) and pepsase were significantly lower in the untreated rats than in normal control rats and SJZD group rats (P < 0.05). Histopathological analysis showed there were significant pathological changes in the untreated rats compared with the normal control group and SJZD group rats. PLS-DA score plots of the untreated group rats clustered separately from control rats, whereas SJZD group rats clustered closely to normal control rats. Twenty potential biomarkers, including phospholipid and fatty acids, were screened. The relative content of 20 metabolites showed significant differences in the untreated group compared with control and SJZD groups (p < 0.05). Six potentially perturbed metabolic pathways were found, which might be potential targets pathways for SJZD intervention in spleen deficiency syndrome.
Conclusion: Metabolomics approach is an effective tool for understanding the therapeutic mechanisms of SJZD.
Keywords: Si–jun–zi decoction, Spleen deficiency syndrome, Metabolomics, LC-Q-TOF/MS
